Weakness in this biotech stock is a buying opportunity: Mizuho

July 31, 2026 9:00 AM

Mizuho reiterated an Outperform rating and $65 price target on a key biotech stock in a note on Friday, telling ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found